On 22 June 2021, ImmunoIVD officially joined the European Alliance for Newborn Screening in SMA as a Member Company. View the other Members of the Alliance here. ImmunoIVD is a Swedish company based in Nacka Strand, south of Stockholm, that was founded in 2015 by researchers who wanted to develop a sensitive SCID assay, suitable for usage in routine newborn screening laboratories. In addition, they subsequently developed a screening kit for SCID and SMA.
They are a specialized, research-intensive company keeping the focus on developing rapid and effective assays for newborn screening to facilitate early detection, prompt treatment, and more successful outcomes for children affected by primary immunodeficiencies and other rare diseases.
ImmunoIVD shares the goal of the Alliance to reduce the time it takes for children born with SMA to be diagnosed. We warmly welcome them to the Alliance and look forward to working closely together to make that goal a reality for newborns in Europe born with SMA.